Website: modality.ai   |   LinkedIn: linkedin.com/company/modality-ai

Measuring the Brain Through Voice and Face

How Dr. David Suendermann-Oeft and Modality.AI are making neurological assessment objective, remote, and scalable

At a glance

  • Company:AI (modality.ai)
  • Headquarters: San Francisco, CA
  • Focus: AI-driven multimodal assessment for neurological and psychiatric conditions in clinical trials
  • Platform: Tina, a virtual clinical guide that runs in a web browser, with no app or special software needed
  • Working with PSG on: Business development with biotech and emerging pharma

Two decades of teaching machines to listen

Long before “AI” became a buzzword, David Suendermann-Oeft was building systems that understand how people speak.

David, Modality.AI’s founder and CEO, has spent more than 20 years in industrial and academic R&D across speech processing, natural language processing, dialog systems, and multimodal AI. His career runs from Siemens, RWTH Aachen, UPC Barcelona, USC, and Columbia to SpeechCycle and Synchronoss in New York, then to Director of Research at Educational Testing Service in San Francisco. Along the way he served as Professor of Computer Science, Department Head, and Director of the DIAMONDS research center at Baden-Württemberg Cooperative State University in Stuttgart.

His output reflects that depth: more than 180 publications and patents, two books, over 3,600 citations, and roles as an evaluator and innovation expert for the European Commission and the U.S. National Science Foundation. He’s also a Siemens PhD Fellow and an ETS SPOT Award winner.

Modality.AI is where all of that comes together, applying decades of speech and language science to some of medicine’s hardest measurement problems.

The problem: CNS endpoints that are hard to measure

In neurology and psychiatry, many clinical endpoints still depend on in-clinic rating scales. Assessments happen infrequently, scores can vary from one rater to the next, and travel is a real burden for patients with ALS, Parkinson’s, or Alzheimer’s disease. That makes trials slower, noisier, and more expensive.

The solution: Tina

Modality.AI’s answer is Tina, a virtual guide that leads participants through a standardized assessment from any browser, at home or at the clinic site. While Tina runs the session, Modality’s AI analyzes speech, language, facial movement, cognitive, and behavioral signals to produce objective, repeatable measurements.

  • Objective and standardized: the same administration every time, which cuts down rater-to-rater variability
  • Remote or site-based: built for decentralized, hybrid, and traditional trials
  • Longitudinal: frequent check-ins capture change between clinic visits
  • Broad CNS coverage: applied in ALS, Alzheimer’s disease and MCI, Parkinson’s disease, schizophrenia, depression, and autism

Validated by science, backed by partners

Modality.AI’s platform has been developed and validated alongside clinical and research partners including MIT, Mass General Hospital, and Harvard Medical School, with NIH support for work in ALS and other conditions. In 2026, the company announced a collaboration with Amprion that pairs Amprion’s molecular biomarkers with Modality’s AI-enabled digital assessments to characterize neurodegenerative disease more precisely.